You can buy or sell ASRT and other stocks, options, ETFs, and crypto commission-free!
Assertio Therapeutics, Inc. engages in the manufacture and distribution of pharmaceutical products to treat pain and other central nervous system conditions. Its brands include Gralise, Zipsor, Lazanda, Cambia, NUCYNTA ER and NUCYNTA. Read More The firm focuses on neurology, orphan and specialty medicines. The company was founded by John W. Shell on August 7, 1995 and is headquartered in Lake Forest, IL.
Lake Forest, Illinois
52 Week High
52 Week Low
Weekly CFO Buys Highlight
According to GuruFocus Insider Data, the recent chief financial officer buys were Forterra Inc. (NASDAQ:FRTA), HC2 Holdings Inc. (NYSE:HCHC) and Assertio Therapeutics Inc. (NASDAQ:ASRT). Forterra CFO bought 36,745 shares Executive Vice President and CFO Charles Rodney Brown bought 36,745 shares for $4.16 per share on March 15. Since then, the share price has declined 1.92%. Forterra has a market cap of $261.940 million; its shares were traded around $4.08. The company has a price-sales ratio of 0.18. Fo...
Assertio Therapeutics beats investor lawsuit over opioid marketing
Assertio Therapeutics Inc has won the dismissal of a shareholder lawsuit accusing it of misleading investors about the extent to which its growth was fueled by marketing its Nucynta opioid painkillers for off-label purposes.
Guru FocusMar 11
Assertio Therapeutics Inc (ASRT) Files 10-K for the Fiscal Year Ended on December 31, 2018
Assertio Therapeutics Inc (NASDAQ:ASRT) files its latest 10-K with SEC for the fiscal year ended on December 31, 2018. Depomed Inc is a specialty pharmaceutical company focused on pain and other conditions and diseases of the central nervous system.
Expected May 9, After Hours